{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:54Z","timestamp":1794315414936,"version":"4.9.0"},"reference-count":50,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In a large series of White patients with refractory uveitis due to Beh\u00e7et disease (BD) being treated with infliximab (IFX), we assessed (1) long-term efficacy and safety of IFX, and (2) IFX optimization when ocular remission was achieved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressant agents treated 103 patients\/185 affected eyes with IFX as first biologic therapy in the following intervals: 3\u20135 mg\/kg intravenous at 0, 2, 6, and then every 4\u20138 weeks. The main outcome variables were analyzed at baseline, first week, first month, sixth month, first year, and second year of IFX therapy. After remission, based on a shared decision between patient and clinician, IFX optimization was performed. Efficacy, safety, and cost of IFX therapy were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the whole series (n = 103), main outcome variables showed a rapid and maintained improvement, reaching remission in 78 patients after a mean IFX duration of 31.5 months. Serious adverse events were observed in 9 patients: infusion reactions (n = 4), tuberculosis (n = 1),<jats:italic>Mycobacterium avium<\/jats:italic>pneumonia (n = 1), severe oral ulcers (n = 1), palmoplantar psoriasis (n = 1), and colon carcinoma (n = 1). In the optimization subanalysis, the comparative study between optimized and nonoptimized groups showed (1) no differences in clinical characteristics at baseline, (2) similar maintained improvement in most ocular outcomes, (3) lower severe adverse events, and (4) lower mean IFX costs in the optimized group (\u20ac4826.52 vs \u20ac9854.13 per patient\/yr).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IFX seems to be effective and relatively safe in White patients with refractory BD uveitis. IFX optimization is effective, safe, and cost-effective.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.200300","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T16:39:11Z","timestamp":1601570351000},"page":"741-750","source":"Crossref","is-referenced-by-count":27,"title":["Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Beh\u00e7et Disease: National Study of 103 White Patients"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6633","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Mart\u00edn-Varillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Atienza-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Calvo-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"S\u00e1nchez-Burs\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Hern\u00e1ndez-Garfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Valls-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00ed","family":"Sellas-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ma\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cruz","family":"Fern\u00e1ndez-Espartero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vega","family":"Jovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Peiteado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D\u00edaz","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Aurrecoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Caracuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo J.","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Raya","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Vegas-Revenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosal\u00eda","family":"Demetrio-Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-8847","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Beh\u00e7et\u2019s Disease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"2022102904450619000_48.5.741.1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.723112"},{"key":"2022102904450619000_48.5.741.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"2022102904450619000_48.5.741.3","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.123554"},{"key":"2022102904450619000_48.5.741.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.032"},{"key":"2022102904450619000_48.5.741.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.022"},{"key":"2022102904450619000_48.5.741.6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.berh.2016.07.005","article-title":"Advancements in the management of uveitis","volume":"30","author":"Schwartzman","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022102904450619000_48.5.741.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"2022102904450619000_48.5.741.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"2022102904450619000_48.5.741.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu266"},{"key":"2022102904450619000_48.5.741.10","first-page":"S34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study","volume":"34","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022102904450619000_48.5.741.11","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.2698"},{"key":"2022102904450619000_48.5.741.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.174888"},{"key":"2022102904450619000_48.5.741.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.194464"},{"key":"2022102904450619000_48.5.741.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"},{"key":"2022102904450619000_48.5.741.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem101"},{"key":"2022102904450619000_48.5.741.16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","article-title":"Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus","volume":"35","author":"Bou","year":"2015","journal-title":"Rheumatol Int"},{"key":"2022102904450619000_48.5.741.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"2022102904450619000_48.5.741.18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10384-012-0202-z","article-title":"Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis","volume":"57","author":"Matsuda","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"2022102904450619000_48.5.741.19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701689"},{"key":"2022102904450619000_48.5.741.20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2022102904450619000_48.5.741.21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology"},{"key":"2022102904450619000_48.5.741.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"2022102904450619000_48.5.741.23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022102904450619000_48.5.741.24","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"2022102904450619000_48.5.741.25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"2022102904450619000_48.5.741.26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10067-018-4069-3","article-title":"Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis","volume":"38","author":"Fabiani","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2022102904450619000_48.5.741.27","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s10067-018-4133-z","article-title":"Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022102904450619000_48.5.741.28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","article-title":"Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients","volume":"38","author":"Fabiani","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2022102904450619000_48.5.741.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-010-9372-1"},{"key":"2022102904450619000_48.5.741.30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"key":"2022102904450619000_48.5.741.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev356"},{"key":"2022102904450619000_48.5.741.32","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: national multicenter study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022102904450619000_48.5.741.33","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"2022102904450619000_48.5.741.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2022102904450619000_48.5.741.35","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022102904450619000_48.5.741.36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022102904450619000_48.5.741.37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-R\u00edo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022102904450619000_48.5.741.38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/09273948.2016.1231331","article-title":"Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review","volume":"25","author":"Calvo-R\u00edo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"2022102904450619000_48.5.741.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.12.019"},{"key":"2022102904450619000_48.5.741.40","first-page":"652","article-title":"Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review","volume":"36","author":"Palmou-Fontana","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2022102904450619000_48.5.741.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)34001-0"},{"key":"2022102904450619000_48.5.741.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.034"},{"key":"2022102904450619000_48.5.741.43","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.70.8.589"},{"key":"2022102904450619000_48.5.741.44","doi-asserted-by":"publisher","DOI":"10.1159\/000055677"},{"key":"2022102904450619000_48.5.741.45","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002847"},{"key":"2022102904450619000_48.5.741.46","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-IL6-receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: multicenter retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology"},{"key":"2022102904450619000_48.5.741.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"2022102904450619000_48.5.741.48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes130"},{"key":"2022102904450619000_48.5.741.49","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"2022102904450619000_48.5.741.50","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T11:45:38Z","timestamp":1667043938000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,1]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.3899\/jrheum.200300"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200300","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}